Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2020-12-15 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
创业板向特定对象发行股票上市公告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市公告书" which translates to "Listing Announcement" for a specific issuance of shares by Betta Pharmaceuticals Co., Ltd. It details the issuance of 10,138,621 shares at a price of 98.83 yuan per share, the total funds raised, the listing date, the lock-up period for the shares, and the involved parties such as underwriters, auditors, and legal counsel. The document includes detailed information about the issuance process, regulatory approvals, share allocation, and shareholder information. This is a formal announcement related to a capital raising event through a private placement of shares and the subsequent listing of these shares on the Shenzhen Stock Exchange. It is not a full financial report, earnings release, or management discussion, but rather an official announcement of a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is not merely a brief announcement or a report publication notice.
2020-12-15 Chinese
董事、监事和高级管理人员持股情况变动报告
Director's Dealing Classification · 95% confidence The document is titled as a report on changes in shareholdings of directors, supervisors, and senior management of Betta Pharmaceuticals Co., Ltd. It details the shareholding numbers before and after a specific stock issuance event, including the dilution effect on their ownership percentages. The content focuses on insider shareholding changes rather than a general financial report or announcement. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives. The document length is short (1675 characters) and contains detailed shareholding data, not just an announcement or certification. Therefore, the appropriate classification is 'DIRS'.
2020-12-15 Chinese
关于在研新药BPI-43487获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving clinical trial approval for a new drug (BPI-43487) from the National Medical Products Administration. It includes details about the drug, the approval notice, and a risk warning. The document is short (1314 characters) and does not contain financial statements, earnings data, or detailed management discussion. It is an announcement of a regulatory approval event rather than a financial report or management update. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-12-14 Chinese
股东减持股份预披露的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from a company disclosing a shareholder's plan to reduce their shareholding. It details the shareholders involved, the number of shares to be reduced, the methods of reduction (such as centralized bidding or block trades), the timing, and the reasons for the reduction. There is no financial report, earnings data, or management discussion. The document is focused on the notification of a planned transaction involving the company's own shares by insiders or significant shareholders. This fits the definition of a 'Transaction in Own Shares' filing, which reports on share repurchases or sales by the company or its shareholders. The document length is about 2500 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is POS (Transaction in Own Shares).
2020-12-11 Chinese
独立董事关于第三届董事会第十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion regarding a specific board meeting agenda item about the sale of a subsidiary's equity. It references compliance with regulatory guidelines and internal company rules, and it is signed by independent directors. The content focuses on governance and board-level approval of a transaction, not on financial results, audit, or detailed financial reporting. The document length is short (840 characters), and it is a formal opinion related to board matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2020-12-10 Chinese
关于梦工场控股出售其子公司股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 贝达药业股份有限公司 regarding the sale of its subsidiary's equity to a related party. It details the transaction overview, parties involved, financial data of the subsidiary, pricing policy, transaction agreement, and approvals by the board and independent directors. The content focuses on a specific capital transaction involving related parties and includes financial figures related to the transaction but does not present a full financial report or earnings release. It is not an annual or interim report, audit report, earnings release, or management discussion. The document is a formal disclosure of a capital transaction (sale of subsidiary equity) and related party transaction, which fits the definition of a Capital/Financing Update (CAP). The document length is about 4604 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-12-10 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.